Stock IOBT IO BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News IO Biotech, Inc.

Equities

IOBT

US4497781090

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.42 USD -2.07% Intraday chart for IO Biotech, Inc. -4.05% -24.47%
Apr. 26 IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors CI
Apr. 15 IO Biotech Announces Marjan Shamsaei as Senior Vice President CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors
CI
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
IO Biotech : Corporate Deck April 2024
PU
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
AQ
IO Biotech Announces Marjan Shamsaei as Senior Vice President
CI
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
AQ
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103
CI
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
AQ
IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer
CI
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting
CI
IO Biotech : Corporate Deck March 2024
PU
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
AQ
IO Biotech to Present at 44th Annual Cowen Health Care Conference
AQ
IO Biotech Doses First Patient in Phase 2 Trial of Melanoma Treatment
MT
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
AQ
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
CI
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IOBT Stock
  4. News IO Biotech, Inc.